Literature DB >> 12669954

Binding and cytotoxicity of HPMA copolymer conjugates to lymphocytes mediated by receptor-binding epitopes.

Aijun Tang1, Pavla Kopeiková, Jindrich Kopeckevá.   

Abstract

PURPOSE: Studies on the recognition of epitopes presented on a template peptide showed the potential of nonapeptide-related sequences to act as biorecognition sites for the B-cell CD21 receptor. This study was intended to evaluate the capability of three epitope sequences to mediate specific cell binding and to enhance the cytotoxicity of HPMA copolymer conjugates.
METHODS: HPMA copolymer conjugates were synthesized containing three different epitopes at various contents and either a fluorescent marker or doxorubicin (DOX). The binding and cytotoxicity of the conjugates to CD21+ Raji B cells and CD21- HSB-2 T cells were evaluated.
RESULTS: The epitope-containing conjugates were found to bind to Raji cells at different apparent affinities depending on epitope structure and content. The conjugates generally possessed higher affinities for Raji cells than for HSB-2 cells. Targeted HPMA copolymer-DOX conjugates exhibited higher cytotoxicities than the nontargeted conjugate, likely indicative of enhanced internalization by receptor-mediated endocytosis. HSB-2 cells were more sensitive to both free and polymer-bound DOX than Raji cells; however, the enhancement of cytotoxicity of the conjugates by incorporation of epitopes was more pronounced for Raji cells.
CONCLUSIONS: The results verified the concept of using receptor-binding epitopes as targeting moieties in HPMA copolymer conjugates for the delivery of anticancer drugs to lymphoma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669954     DOI: 10.1023/a:1022639701388

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21).

Authors:  M W Hess; M G Schwendinger; E L Eskelinen; K Pfaller; M Pavelka; M P Dierich; W M Prodinger
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

2.  Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function.

Authors:  S E Henson; D Smith; S A Boackle; V M Holers; D R Karp
Journal:  J Immunol Methods       Date:  2001-12-01       Impact factor: 2.303

3.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

5.  Polymerizable Fab' antibody fragments for targeting of anticancer drugs.

Authors:  Z R Lu; P Kopecková; J Kopecek
Journal:  Nat Biotechnol       Date:  1999-11       Impact factor: 54.908

6.  Complement C3d,g/Epstein-Barr virus receptor density on human B-lymphocytes estimated by immunoenzymatic assay and immunocytochemistry.

Authors:  R Rask; J M Rasmussen; H V Hansen; P Bysted; S E Svehag
Journal:  J Clin Lab Immunol       Date:  1988-03

Review 7.  HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action.

Authors:  J Kopecek; P Kopecková; T Minko; Z Lu
Journal:  Eur J Pharm Biopharm       Date:  2000-07       Impact factor: 5.571

8.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

Authors:  T Minko; P Kopecková; V Pozharov; J Kopecek
Journal:  J Control Release       Date:  1998-07-31       Impact factor: 9.776

9.  Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.

Authors:  V Omelyanenko; P Kopecková; C Gentry; J Kopecek
Journal:  J Control Release       Date:  1998-04-30       Impact factor: 9.776

10.  Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody.

Authors:  B Ríhová; P Kopecková; J Strohalm; P Rossmann; V Vĕtvicka; J Kopecek
Journal:  Clin Immunol Immunopathol       Date:  1988-01
View more
  11 in total

Review 1.  Smart self-assembled hybrid hydrogel biomaterials.

Authors:  Jindřich Kopeček; Jiyuan Yang
Journal:  Angew Chem Int Ed Engl       Date:  2012-07-23       Impact factor: 15.336

Review 2.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

3.  A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.

Authors:  Ho Lun Wong; Andrew M Rauth; Reina Bendayan; Janet L Manias; Manisha Ramaswamy; Zengshe Liu; Sevim Z Erhan; Xiao Yu Wu
Journal:  Pharm Res       Date:  2006-06-24       Impact factor: 4.200

Review 4.  Nanomaterials for cancer therapy and imaging.

Authors:  Ki Hyun Bae; Hyun Jung Chung; Tae Gwan Park
Journal:  Mol Cells       Date:  2011-02-25       Impact factor: 5.034

5.  Two-step fluorescence screening of CD21-binding peptides with one-bead one-compound library and investigation of binding properties of N-(2-hydroxypropyl)methacrylamide copolymer-peptide conjugates.

Authors:  Hui Ding; Wolfgang M Prodinger; Jindrich Kopecek
Journal:  Biomacromolecules       Date:  2006-11       Impact factor: 6.988

Review 6.  Macromolecular therapeutics.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

7.  Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates.

Authors:  Huaizhong Pan; Monika Sima; Pavla Kopecková; Kuangshi Wu; Songqi Gao; Jihua Liu; Dong Wang; Scott C Miller; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2008-05-28       Impact factor: 4.939

8.  Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers.

Authors:  Huili Guan; Michael J McGuire; Shunzi Li; Kathlynn C Brown
Journal:  Bioconjug Chem       Date:  2008-08-19       Impact factor: 4.774

9.  HPMA copolymers: origins, early developments, present, and future.

Authors:  Jindrich Kopecek; Pavla Kopecková
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

10.  Functionalization of Carbon Nanomaterial Surface by Doxorubicin and Antibodies to Tumor Markers.

Authors:  Olena M Perepelytsina; Olena M Yakymchuk; Mychailo V Sydorenko; Olga N Bakalinska; Francesco Bloisi; Luciano Rosario Maria Vicari
Journal:  Nanoscale Res Lett       Date:  2016-06-29       Impact factor: 4.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.